These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 39174693)

  • 1. Machine learning developed a macrophage signature for predicting prognosis, immune infiltration and immunotherapy features in head and neck squamous cell carcinoma.
    Wang Y; Mou YK; Liu WC; Wang HR; Song XY; Yang T; Ren C; Song XC
    Sci Rep; 2024 Aug; 14(1):19538. PubMed ID: 39174693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature.
    Liu L; Liu Q
    Sci Rep; 2024 Apr; 14(1):9914. PubMed ID: 38688945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
    Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
    BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma.
    Huang J; Xu Z; Wang Z; Zhou C; Shen Y
    Curr Cancer Drug Targets; 2024; 24(8):804-819. PubMed ID: 38310463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP63 transcriptionally regulates SLC7A5 to suppress ferroptosis in head and neck squamous cell carcinoma.
    Chen Z; Cai H; Ye W; Wu J; Liu J; Xie Y; Feng S; Jin Y; Lv Y; Ye H; Cai C; Cai G
    Front Immunol; 2024; 15():1445472. PubMed ID: 39234254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
    Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
    BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.
    Wu Z; Zhu Z; Wu W; Hu S; Cao J; Huang X; Xie Q; Deng C
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3143-3156. PubMed ID: 38507078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 9. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
    Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
    Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel CAF-cancer cell crosstalk-related gene prognostic index based on machine learning: prognostic significance and prediction of therapeutic response in head and neck squamous cell carcinoma.
    Xu Y; Li J; Wang J; Deng F
    J Transl Med; 2024 Jul; 22(1):645. PubMed ID: 38982511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
    Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
    Cell Oncol (Dordr); 2024 Aug; 47(4):1129-1148. PubMed ID: 38315286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of two distinct head and neck squamous cell carcinoma subtypes based on fatty acid metabolism-related signatures: Implications for immunotherapy and chemotherapy.
    Zou J; Dai Y; Xu G; Kai Y; Lan L; Zhang J; Wang Y
    Medicine (Baltimore); 2024 Apr; 103(16):e37824. PubMed ID: 38640298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
    Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer.
    Cao H; Lan T; Kuang S; Wang L; Li J; Li Q; Li Y; Xu Q; Chen Q; Ren S; Lan C; Ouyang N; Liao J; Huang Y; Li J
    Drug Resist Updat; 2024 Sep; 76():101095. PubMed ID: 38986165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
    Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
    Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of immunogenic cell death-related damage-related molecular patterns (DAMPs) to predict outcomes in patients with head and neck squamous cell carcinoma.
    Zhang J; Shi X; Wang M; Zhai R; Wang M; Gong Z; Ni Z; Xu T; Zhu W; Liu L
    J Cancer Res Clin Oncol; 2024 May; 150(5):240. PubMed ID: 38713284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mast cell marker gene signature in head and neck squamous cell carcinoma.
    Cai Z; Tang B; Chen L; Lei W
    BMC Cancer; 2022 May; 22(1):577. PubMed ID: 35610596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
    Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
    Front Immunol; 2021; 12():791621. PubMed ID: 35003112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.